Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Supportive and palliative care

1264MO - Development and validation of a unifying pre-treatment decision tool for intracranial and extracranial metastasis-directed radiotherapy


10 Sep 2022


Mini Oral session: Supportive and palliative care


Clinical Research;  Radiation Oncology;  Supportive and Palliative Care

Tumour Site


Roman Kowalchuk


Annals of Oncology (2022) 33 (suppl_7): S581-S591. 10.1016/annonc/annonc1066


R.O. Kowalchuk1, T.C. Mullikin2, W.G. Breen1, H.C. Gits1, M. Florez3, B.S. De3, W.S. Harmsen4, P.S. Rose5, B.L. Siontis6, B.A. Costello6, J.M. Morris7, J.J. Lucido8, K.R. Olivier1, B.J. Stish1, N.N. Laack1, S.S. Park1, D. Owen1, A.J. Ghia3, P.D. Brown1, K.W. Merrell9

Author affiliations

  • 1 Radiation Oncology, Mayo Clinic, 55905 - Rochester/US
  • 2 Radiation Oncology, Duke Cancer Center - Duke University Medical Center, 27710 - Durham/US
  • 3 Radiation Oncology, MD Anderson Cancer Center, 77030 - Houston/US
  • 4 Statistics, Mayo Clinic, 55905 - Rochester/US
  • 5 Orthopedic Surgery, Mayo Clinic, 55905 - Rochester/US
  • 6 Medical Oncology, Mayo Clinic, 55905 - Rochester/US
  • 7 Radiology, Mayo Clinic, 55905 - Rochester/US
  • 8 Medical Physics, Mayo Clinic, 55905 - Rochester/US
  • 9 Radiation Oncology, Mayo Clinic Cancer Center, 55905 - Rochester/US


Login to access the resources on OncologyPRO.

Abstract 1264MO


Metastasis-directed therapy (MDT) has the potential to improve clinical outcomes and even overall survival (OS). However, prognostication and appropriate patient selection for MDT remain challenging. We aimed to develop a unifying model predictive of OS for patients with intracranial and extracranial disease to refine patient selection for MDT and clinical trials.


We assembled a multi-institutional cohort of patients treated with MDT to spine, brain, and/or lung metastases. Treatments included stereotactic body radiation therapy, radiosurgery, and whole brain radiation therapy. Candidate variables for recursive partitioning analysis were selected per prior studies: ECOG performance status, time from primary diagnosis (TPD), number of additional non-target organ systems involved (NOS), and intracranial metastases.


A database of 1,362 patients was assembled with 424 intracranial, 352 lung, and 607 spinal treatments (n=1,383). Of patients treated for intracranial disease, 75% also had extracranial disease. Treatments were split into training (TC) (70%, n=968) and internal validation (IVC) (30%, n=415) cohorts. The TC had median ECOG of 0 (interquartile range [IQR]: 0-1), NOS of 1 (IQR: 0-1), and OS of 18 months (IQR: 7-35). The resulting model components and weights were: ECOG = 0, 1, and > 1 (0, 1, and 2); 0, 1, and > 1 NOS (0, 1, and 2); and intracranial target (2). The model demonstrated high concordance in the TC (0.72) and IVC (0.72). The score demonstrated concordance of 0.65-0.71 for each target site (spine, brain, and lung), and each variable used in the model met statistical significance (p<0.0001).


This pre-treatment decision tool identifies patients with the longest survival after MDT, indicating a patient population with systemic disease who may benefit most from aggressive local therapy. This model represents a unifying model applicable in settings of both intracranial and extracranial disease. Carefully selected patients may benefit from MDT even in the presence of intracranial disease.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


R.O. Kowalchuk: Financial Interests, Personal, An immediate family member of Dr. Kowalchuk is employed by GE Healthcare: GE Healthcare. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.